Results 131 to 140 of about 8,133 (247)

Body Composition Remodelling During GLP‐1‐Based Therapy: A Systematic Review and Meta‐Analysis Using a Hierarchical Physiological Framework

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Background Body composition changes during glucagon‐like peptide‐1 (GLP‐1)‐based therapy remain incompletely characterized, particularly regarding their effects on adiposity, muscle quantity, and muscle quality. We conducted a systematic review and meta‐analysis using a predefined physiological framework to evaluate body composition ...
Maria Luizza Lopes Menezes, Maria Eduarda Güntzel Chiappa, Rodrigo Fuentes Kloss, Marcelo Tuesta, Paula Santos, Alberto Souza Sá Filho, Gaspar R. Chiappa   +6 more
wiley   +1 more source

Vegetable‐First Meal Sequence Suppresses Postprandial Glycaemic Excursions and Variability in Young Women With High‐Risk Phenotype for Early‐Onset Type 2 Diabetes: A 4‐Arm Randomized Crossover Trial With Continuous Glucose Monitoring

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Managing postprandial glycaemic variability is crucial for preventing metabolic diseases. Although the effects of a vegetable‐first meal sequence on blood glucose levels have been well documented, there is limited research on consecutive, repeated meal sequencing for healthy young women.
Minji Choi, Soyoon Lee, Eujean Bang, Ijae Seo, Jieun Lee, Sehyun Joo, Hyeonseo Kim, Song Vogue Ahn, Yuri Kim, Jieun Oh   +9 more
wiley   +1 more source

Therapies for Cardiovascular‐Kidney‐Liver‐Metabolic Syndrome: Reappraisal of Fibrates

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Cardiovascular disease, chronic kidney disease (CKD), type 2 diabetes mellitus (T2DM), obesity and metabolic dysfunction‐associated steatohepatitis (MASH) frequently coexist and share overlapping pathophysiology, forming the proposed cardiovascular‐kidney‐liver‐metabolic (CKLM) syndrome.
Virginia Anagnostopoulou, Christoforos K. Travlos, Lucas Lage Marinho, Thomas A. Mavrakanas, João Pedro Ferreira, Abhinav Sharma   +5 more
wiley   +1 more source

Obituary for Prof. Dr. med. Dr. h. c. Werner Creutzfeldt, FRCP [PDF]

, 2006
Burkhard Göke, Göke, Burkhard
core   +1 more source

Efficacy of Luseogliflozin Added to Semaglutide in Patients With Metabolic Dysfunction‐Associated Steatohepatitis and Type 2 Diabetes Mellitus: A Randomised, Open‐Label Trial

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Type 2 diabetes drives the progression of metabolic dysfunction‐associated steatohepatitis (MASH). We evaluated whether antidiabetic therapy, specifically adding sodium–glucose cotransporter 2 (SGLT2) inhibitor to a glucagon‐like peptide‐1 receptor agonist (GLP‐1RA), improves liver histology in adults with biopsy‐proven MASH and type 2 ...
Teruki Miyake, Osamu Yoshida, Shinya Furukawa, Masashi Hirooka, Masanori Abe, Yoshio Tokumoto, Ayumi Kanamoto, Takao Watanabe, Ryo Yano, Yuki Okazaki, Atsushi Yukimoto, Yoshiko Nakamura, Eiji Takeshita, Teru Kumagi, Yoichi Hiasa   +14 more
wiley   +1 more source

Trends in Cost of Care With Tirzepatide in Adults Aged Over 55 Years With Obesity or Overweight Without Diabetes: A Matched Cohort Analysis

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Compare healthcare cost trends among older adults with obesity or overweight treated with tirzepatide versus no treatment. Materials and Methods Retrospective cohort study using real‐world data from US Komodo Research Dataset, 8 November 2022 to 30 September 2025.
Navneet Upadhyay, Ali Bonakdar, Keshab Subedi, Soutrik Banerjee, Benjamin Behrend, Emily R. Hankosky   +5 more
wiley   +1 more source

The molecular mechanisms of incretin resistance in Type 2 Diabetes Mellitus (T2DM). [PDF]

Nutr Diabetes
Albaghlany RM, Mansour AA.
europepmc   +1 more source

SURPASS‐CVOT and the Emerging Biology of Cardiometabolic Benefit

Diabetes, Obesity and Metabolism, EarlyView.
Salvatore Corrao, Francesco Cosentino, Massimo Federici   +2 more
wiley   +1 more source

Cardiorenal Mortality and Safety Outcomes of GLP‐1 Receptor Agonists in Type 2 Diabetes With BMI Below 27 kg/m2: A Target Trial Emulation

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Cardiorenal evidence for glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) derives mainly from trials in overweight or obesity; data in adults with Type 2 diabetes (T2D) and body mass index (BMI) below 27 kg/m2 are limited. Materials and Methods We emulated a target trial in the TriNetX US Collaborative Network (index dates 2020 to ...
Shao‐Chia Chen, Yu‐Nan Huang, Pei‐Yun Li, Jo‐Ching Chen, Gideon Meyerowitz‐Katz, Shun‐Fa Yang, Pen‐Hua Su   +6 more
wiley   +1 more source

Dysfunctional Lipid-Induced Secretion of Glucagon-Like Peptide-2(GLP-2), but Not of Incretins Glucagon-Like Peptide-1(GLP-1)/Glucose-Dependent Insulinotropic Polypeptide(GIP), Promotes Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Onset and Progression Through Gut Barrier Disruption and Endotoxemia. [PDF]

MedComm (2020)
Musso G, Pinach S, Mella A, De Michieli F, Calabrese A, Trifiro D, Petrangolini G, Cassader M, Mariano F, Gambino R.   +9 more
europepmc   +1 more source